雷贝拉唑联合治疗反流性食管炎的临床研究

目的评价雷贝拉唑联合莫沙必利和铝镁加治疗反流性食管炎的临床疗效。方法将127例反流性食管炎患者随机分为治疗组（63例）和对照组（64例），治疗组给予口服雷贝拉唑、莫沙必利和铝镁加综合治疗，对照组则给予奥美拉唑、莫沙必利和铝镁加综合治疗。于治疗8周后复查胃镜及24h食管pH变化，观察两组患者的临床治愈率、镜下治愈率及食管24hpH变化。结果治疗8周，治疗组患者临床疗效显效率为79．5％，总有效率为94．1％。均显著高于对照组的34．0％和71．5％，差异有统计学意义（P〈0．05）；内镜复查治疗组食管炎愈合总有效率为95．3％，明显高于对照组的73．5％，差异有统计学意义（P〈0．05）；与对照组治疗后相比较，治疗组pH〈4总反流时间百分率、总反流次数明显下降（P〈0．05）。结论联合应用雷贝拉唑、莫沙比利和铝镁加治疗反流性食管炎能迅速缓解症状．提高生活质量，疗效显著，值得临床推广应用。

Clinical study of combined treatment of Rabeprazole in reflux esophagitis

Objective To evaluate the clinical effects of Rabeprazole combined with Mosapride and Almagate in the treatment of reflux esophagitis. Methods 127 patients with reflux exsophagitis were randomly divided into two groups： treatment group （n = 63） treated with Rabeprazole combinated with Mosapride and Almagate and control group （n = 64） treated with Omeprazole combined with Mosapride and Almagate for 8 weeks. After 8 weeks, the clinical cure rate, esophagitis gastroscope concrescence rate and esophageal 24 h pH were compared in two groups. Results After 8 weeks, the obviously remission rate and total effective rate in two groups was 79.5% vs 34% and 94.1% vs 71.5%, （P 〈 0.05）. Esophagitis gastroscope concrescence rate was 95.3% vs 73.5% （P 〈 0.05）. Compared with control group after treatment, the treatment group pH 〈 4 total reflux time, percentage of total reflux episodes significantly decreased （P 〈 0.05）. Conclusion Rebeprazole combined with Mosapride and Almagate can quickly alleviate symptoms of reflux esophagitis, improve the quality of life, which is worthy of promotion in clinic.